Eli Lilly, Novo Nordisk, and AbbVie are seeking regulatory approval via 510(k) while maintaining their established market leadership.

The entities involved

• Eli Lilly and Company →

  American pharmaceutical company

  • ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
  • The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59
• Novo Nordisk →

  Danish pharmaceutical company

  • BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Mon 10:09
  • CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.Mon 00:08
• AbbVie →

  pharmaceutical company

  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
  • AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48

Related events

• Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.Sep 14
• Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.Sep 3
• Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.Jun 8
• Novo Nordisk expanded its pediatric label franchise on September 15, 2026.Sep 17
• Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.Jun 8